See more : Surgutneftegas Public Joint Stock Company (SNGS.ME) Income Statement Analysis – Financial Results
Complete financial analysis of Jiangsu Recbio Technology Co., Ltd. (2179.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jiangsu Recbio Technology Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- G&P Acquisition Corp. (GAPA-UN) Income Statement Analysis – Financial Results
- EAST WEST HOLDINGS LIMITED (EASTWEST.BO) Income Statement Analysis – Financial Results
- Viking Therapeutics, Inc. (0VQA.L) Income Statement Analysis – Financial Results
- Manitok Energy Inc. (MKRYF) Income Statement Analysis – Financial Results
- Shanghai Haoyuan Chemexpress Co., Ltd. (688131.SS) Income Statement Analysis – Financial Results
Jiangsu Recbio Technology Co., Ltd. (2179.HK)
About Jiangsu Recbio Technology Co., Ltd.
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It is also developing ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; and R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in pre-clinical stage; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. The company was founded in 2011 and is based in Taizhou, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 30.38M | 5.33M | 6.20M | 1.46M | 0.00 |
| Cost of Revenue | 8.04M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 22.34M | 5.33M | 6.20M | 1.46M | 0.00 |
| Gross Profit Ratio | 73.54% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 487.85M | 716.44M | 472.95M | 130.52M | 63.27M |
| General & Administrative | 143.77M | 155.30M | 143.05M | 6.99M | 3.48M |
| Selling & Marketing | 8.47M | 8.65M | 3.46M | 0.00 | 0.00 |
| SG&A | 152.24M | 163.96M | 146.51M | 6.99M | 3.48M |
| Other Expenses | 0.00 | -5.33M | -6.20M | 9.97M | 8.05M |
| Operating Expenses | 640.09M | 875.08M | 613.26M | 147.48M | 74.80M |
| Cost & Expenses | 648.12M | 875.08M | 613.26M | 147.48M | 74.80M |
| Interest Income | 32.01M | 23.98M | 10.36M | 2.63M | 2.00M |
| Interest Expense | 0.00 | 3.53M | 56.31M | 37.11M | 76.16M |
| Depreciation & Amortization | 47.88M | 40.94M | 22.46M | 12.76M | 4.33M |
| EBITDA | -569.87M | -847.67M | -590.00M | -134.91M | -68.43M |
| EBITDA Ratio | -1,875.99% | -13,052.21% | -9,517.62% | -9,252.81% | 0.00% |
| Operating Income | -617.75M | -735.97M | -612.46M | -147.67M | -72.75M |
| Operating Income Ratio | -2,033.60% | -13,820.94% | -9,879.90% | -10,128.19% | 0.00% |
| Total Other Income/Expenses | 45.30M | 139.08M | -44.31M | -31.92M | -63.23M |
| Income Before Tax | -572.44M | -736.00M | -657.57M | -179.40M | -138.27M |
| Income Before Tax Ratio | -1,884.46% | -13,821.52% | -10,607.61% | -12,304.53% | 0.00% |
| Income Tax Expense | 0.00 | -16.80M | 45.11M | 31.73M | 65.52M |
| Net Income | -571.96M | -719.20M | -702.67M | -211.13M | -203.79M |
| Net Income Ratio | -1,882.86% | -13,506.10% | -11,335.25% | -14,480.86% | 0.00% |
| EPS | -1.19 | -1.52 | -1.57 | -0.44 | -0.43 |
| EPS Diluted | -1.19 | -1.52 | -1.57 | -0.44 | -0.43 |
| Weighted Avg Shares Out | 480.94M | 474.21M | 448.25M | 479.10M | 479.10M |
| Weighted Avg Shares Out (Dil) | 480.94M | 474.21M | 448.25M | 479.10M | 479.10M |
Source: https://incomestatements.info
Category: Stock Reports